<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232332</url>
  </required_header>
  <id_info>
    <org_study_id>PR-JSZX-2019015F</org_study_id>
    <nct_id>NCT04232332</nct_id>
  </id_info>
  <brief_title>The Phase I Study of Recombinant Human Nerve Growth Factor Injection</brief_title>
  <official_title>The Phase I Study of Recombinant Human Nerve Growth Factor Injection in Healthy Chinese Volunteers on Safety, Tolerability and Pharmacokinetics: Randomized, Double-blind, Placebo-controlled, Single / Multiple Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, placebo-controlled, single/multiple dose study of recombinant&#xD;
      human nerve growth factor injection in healthy Chinese volunteers on safety, tolerability and&#xD;
      pharmacokinetics&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single / multiple dose trial.&#xD;
      recombinant human nerve growth factor injection in healthy Chinese volunteers on safety, and&#xD;
      pharmacokinetics.The volunteers will be given the drug by intramuscular injection. The main&#xD;
      purpose of this trial is to investigate the safety, tolerability , pharmacokinetics and&#xD;
      immunogenicity of Chinese healthy volunteers after intramuscular injection of recombinant&#xD;
      human nerve growth factor injection, to provide a safe dose range for subsequent clinical&#xD;
      trials, as well as a safe and reasonable drug delivery program.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Single dose: 28 days / Multiple dose: 34 days</time_frame>
    <description>Record the number of participants with abnormal laboratory values and/or adverse events,calculate frequency and percentage based on correlation with the investigational drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve (AUC) after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 after injection of single dose/multiple dose</measure>
    <time_frame>Single dose: 24 hours / Multiple doses: 8 days</time_frame>
    <description>To measure the drug concentration in blood samples which collected after injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With anti-drug antibodies</measure>
    <time_frame>Single dose: 28 days / Multiple dose: 34 days</time_frame>
    <description>Percentage of participants with treatment-emergent positive anti-drug antibodies was summarized by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Injury of Optic Nerve</condition>
  <arm_group>
    <arm_group_label>3.75μg (pre test)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7.5μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>75μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>90μg single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30μg multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The dosage will be adjusted according to the actual situation of the trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>45μg multiple dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The dosage will be adjusted according to the actual situation of the trial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human nerve growth factor injection,experimental</intervention_name>
    <description>Intramuscular injection once on the first day according to dose requirements</description>
    <arm_group_label>3.75μg (pre test)</arm_group_label>
    <arm_group_label>7.5μg</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human nerve growth factor injection,single dose</intervention_name>
    <description>Intramuscular injection once on the first day according to dose requirements</description>
    <arm_group_label>15μg single dose</arm_group_label>
    <arm_group_label>30μg single dose</arm_group_label>
    <arm_group_label>45μg single dose</arm_group_label>
    <arm_group_label>60μg single dose</arm_group_label>
    <arm_group_label>75μg single dose</arm_group_label>
    <arm_group_label>90μg single dose</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human nerve growth factor injection,multiple dose</intervention_name>
    <description>Intramuscular injection once daily for 7 days according to dose requirements</description>
    <arm_group_label>30μg multiple dose</arm_group_label>
    <arm_group_label>45μg multiple dose</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-45 years old, including boundary value;&#xD;
&#xD;
          2. The body weight meets the standard, the body weight of male volunteers is not less&#xD;
             than 50kg, the body weight of female volunteers is not less than 45kg, the body mass&#xD;
             index is in the range of 19-24kg / m2, the body mass index = body weight (kg) / height&#xD;
             (M2);&#xD;
&#xD;
          3. volunteers participated in the study voluntarily and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Take any prescription or over-the-counter drugs within 2 weeks before screening;&#xD;
&#xD;
          2. Those who have been vaccinated within 3 months before screening;&#xD;
&#xD;
          3. Those who participated in any clinical trial within 3 months before screening;&#xD;
&#xD;
          4. Those who lost blood or donated more than 200 ml blood within 4 weeks before screening&#xD;
             or who intend to donate blood during the study or within 4 weeks after the end of the&#xD;
             study;&#xD;
&#xD;
          5. Diseases with clinical significance within 2 weeks before screening;&#xD;
&#xD;
          6. Those who had major surgery, trauma or hospitalization within 6 months before&#xD;
             screening;&#xD;
&#xD;
          7. There is tattoo or other influence on the injection site to observe the skin&#xD;
             condition;&#xD;
&#xD;
          8. Patients with history of central nervous system, mental system, cardiovascular system,&#xD;
             urinary system, digestive system, respiratory system, metabolism system, blood system,&#xD;
             immune system, endocrine system and skeletal muscle system may endanger the safety of&#xD;
             the subjects or affect the research results according to the judgment of the&#xD;
             researchers;&#xD;
&#xD;
          9. There is a significant history of allergy in clinic, especially the history of drug&#xD;
             allergy, especially the allergy to any component of zx1305 injection;&#xD;
&#xD;
         10. The five items of hepatitis B (hepatitis B surface antigen, hepatitis B surface&#xD;
             antibody, hepatitis B e antigen, hepatitis B e antibody, hepatitis B core antibody),&#xD;
             hepatitis C antibody, syphilis specific antibody or AIDS joint test have clinical&#xD;
             significance;&#xD;
&#xD;
         11. It is suspected that there is alcohol dependence, and the average alcohol intake in&#xD;
             the first half year of screening is more than 2 units per day (1 unit = 10ml alcohol,&#xD;
             i.e. 1 unit = 200ml beer with 5% alcohol or 25ml spirits with 40% alcohol or 83ml wine&#xD;
             with 12% alcohol) or the alcohol test is positive;&#xD;
&#xD;
         12. Those who smoked more than 5 cigarettes per day in the first half year of screening;&#xD;
&#xD;
         13. Those who had a history of drug abuse or had taken drugs within one year before&#xD;
             screening, or who were positive in urine test of ketamine, morphine, methamphetamine,&#xD;
             dimethyldioxygoamphetamine and tetrahydrocannabinolic acid;&#xD;
&#xD;
         14. Women who are positive in pregnancy, lactation, blood pregnancy or who have not taken&#xD;
             effective contraceptive measures in the last month, and men or women who are not&#xD;
             willing to take effective non drug contraceptive measures during the whole trial&#xD;
             period and who are not willing to take effective contraceptive measures within one&#xD;
             year after the end of the trial;&#xD;
&#xD;
         15. The condition of peripheral venous access is poor (difficult to collect blood);&#xD;
&#xD;
         16. There are other reasons that the researchers think should not be selected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng Wu</last_name>
    <phone>010-58268422</phone>
    <email>bjtrec@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yi Zhang</last_name>
    <phone>025-58310595</phone>
    <email>Zhang.Yi@xintrum.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wu</last_name>
      <phone>010-58268422</phone>
      <email>bjtrec@126.com</email>
    </contact>
    <investigator>
      <last_name>Xiuli Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Optic Nerve Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

